• Jacob Otu
  • Lindsay Kendall
  • Audrey Forson
  • Awewura Kwara
  • Samuel Kudzawu
  • Aderemi O. Kehinde
  • Oludele Adebiyi
  • Kayode Salako
  • Ignatius Baldeh
  • Aisha Jallow
  • Mamadou Jallow
  • Anoumou Dagnra
  • Kodjo Disse
  • Essosimna A. Kadanga
  • Emmanuel Oni Idigbe
  • Catherine Onubogu
  • Nneka Onyejepu
  • Aissatou Gaye-Diallo
  • Awa Ba-Diallo
  • Paulo Rabna
  • Morto Mane
  • Moumine Sanogo
  • Zingue Dezemon
  • Adama Sanou
  • Madikay Senghore
  • Brenda A. Kwambana-Adams
  • Edward Demba
  • Tutty Faal-Jawara
  • Samrat Kumar
  • Leopold D. Tientcheu
  • Adama Jallow
  • Samba Ceesay
  • Ifedayo Adetifa
  • Assan Jaye
  • Mark J. Pallen
  • Beate Kampmann
  • Richard A. Adegbola
  • Souleymane Mboup
  • Tumani Corrah
  • Martin Antonio

Background: Drug-resistant tuberculosis (TB) is a global public health problem. Adequate management requires baseline drug-resistance prevalence data. In West Africa, due to a poor laboratory infrastructure and inadequate capacity, such data are scarce. Therefore, the true extent of drug-resistant TB was hitherto undetermined. In 2008, a new research network, the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANETAM), was founded, comprising nine study sites from eight West African countries (Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo). The goal was to establish Good Clinical Laboratory Practice (GCLP) principles and build capacity in standardised smear microscopy and mycobacterial culture across partnering laboratories to generate the first comprehensive West African drug-resistance data.

Methods: Following GCLP and laboratory training sessions, TB isolates were collected at sentinel referral sites between 2009-2013 and tested for first-and second-line drug resistance.

Results: From the analysis of 974 isolates, an unexpectedly high prevalence of multi-drug-resistant (MDR) strains was found in new (6 %) and retreatment patients (35 %) across all sentinel sites, with the highest prevalence amongst retreatment patients in Bamako, Mali (59 %) and the two Nigerian sites in Ibadan and Lagos (39 % and 66 %). In Lagos, MDR is already spreading actively amongst 32 % of new patients. Pre-extensively drug-resistant (pre-XDR) isolates are present in all sites, with Ghana showing the highest proportion (35 % of MDR). In Ghana and Togo, pre-XDR isolates are circulating amongst new patients.

Conclusions: West African drug-resistance prevalence poses a previously underestimated, yet serious public health threat, and our estimates obtained differ significantly from previous World Health Organisation (WHO) estimates. Therefore, our data are reshaping current concepts and are essential in informing WHO and public health strategists to implement urgently needed surveillance and control interventions in West Africa.

Originele taal-2Engels
Artikel nummer160
TijdschriftBMC Medicine
Aantal pagina's12
StatusGepubliceerd - 2016

ID: 2668708